Research analysts at HC Wainwright assumed coverage on shares of CytomX Therapeutics Inc (NASDAQ:CTMX) in a research note issued on Monday. The firm set a “buy” rating and a $24.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 34.91% from the stock’s current price.
A number of other equities research analysts also recently issued reports on the stock. Instinet boosted their target price on shares of CytomX Therapeutics from $21.00 to $32.00 and gave the company a “sell” rating in a report on Monday, March 20th. Oppenheimer Holdings Inc. restated a “hold” rating on shares of CytomX Therapeutics in a report on Saturday, March 4th. Zacks Investment Research upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, March 3rd. Nomura began coverage on shares of CytomX Therapeutics in a report on Wednesday, March 1st. They issued a “buy” rating for the company. Finally, Cowen and Company restated a “buy” rating on shares of CytomX Therapeutics in a report on Thursday, February 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $22.67.
Shares of CytomX Therapeutics (NASDAQ:CTMX) opened at 17.79 on Monday. The stock has a 50 day moving average of $13.64 and a 200-day moving average of $12.81. The firm’s market capitalization is $649.66 million. CytomX Therapeutics has a one year low of $9.10 and a one year high of $20.02.
CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, March 2nd. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. CytomX Therapeutics had a negative net margin of 523.78% and a negative return on equity of 52.50%. On average, equities analysts anticipate that CytomX Therapeutics will post ($2.08) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was reported by Mideast Time and is the sole property of of Mideast Time. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.mideasttime.com/cytomx-therapeutics-inc-ctmx-coverage-initiated-by-analysts-at-hc-wainwright/1589150.html.
In related news, CFO Robert C. Goeltz II sold 21,517 shares of the business’s stock in a transaction that occurred on Monday, March 20th. The shares were sold at an average price of $19.81, for a total value of $426,251.77. Following the completion of the sale, the chief financial officer now directly owns 31,306 shares in the company, valued at $620,171.86. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Sean A. Mccarthy sold 14,343 shares of the business’s stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $19.60, for a total transaction of $281,122.80. Following the sale, the insider now owns 16,322 shares of the company’s stock, valued at $319,911.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,203 shares of company stock valued at $922,520. 4.70% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the company. FMR LLC increased its stake in CytomX Therapeutics by 0.3% in the fourth quarter. FMR LLC now owns 5,460,352 shares of the company’s stock valued at $60,009,000 after buying an additional 17,090 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in CytomX Therapeutics during the fourth quarter valued at about $10,152,000. State Street Corp increased its stake in CytomX Therapeutics by 1.7% in the fourth quarter. State Street Corp now owns 275,483 shares of the company’s stock valued at $3,027,000 after buying an additional 4,596 shares in the last quarter. Private Advisor Group LLC increased its stake in CytomX Therapeutics by 0.5% in the fourth quarter. Private Advisor Group LLC now owns 213,177 shares of the company’s stock valued at $2,357,000 after buying an additional 988 shares in the last quarter. Finally, Opaleye Management Inc. increased its stake in CytomX Therapeutics by 6.3% in the fourth quarter. Opaleye Management Inc. now owns 170,000 shares of the company’s stock valued at $1,868,000 after buying an additional 10,000 shares in the last quarter. Institutional investors own 54.31% of the company’s stock.
About CytomX Therapeutics
CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.
Receive News & Ratings for CytomX Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.